Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (3172)	9/21/2005 12:57:24 PM
From: zeta1961	Read Replies (1) \| Respond to of 12215

Wilder..funny, just read the transcript of the CC and came over here to post.. Why does RNVS's projected peak revenue for Cerovive = over a billion per GS(see link below)..I realize that the latter is being tested for hemorrhagic stroke too(but that's only 15% of population... I, not having much(at all) clinical experience in this field, Frieman's comment re: the failed neuroprotectant trials and how if you have a blocked major vessel(s) it's not likely you'll get the drug through..this statement rang true for me.. Interesting, cuz I've met Frieman so his snake journey wasn't surprising..and I know if Marc hadn't had interactions with him over the years, he'd not be so loyal.. Message 21316500 Lastly, Rilke is my scribe mentor(I'm told he took much license with German that drives the translators buggy-g-) as I'm sure my gramar and speling do! Really lastly..I enjoyed the interchange between you, John and quidditch Elisabeth